跳至主要内容
临床试验/NCT05486325
NCT05486325Unknown不适用

Pilot Study of the Endolumik Gastric Calibration Tube for Bariatric Surgery

Endolumik, Inc2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年8月最近更新:
适应症

试验速览

阶段
不适用
入组人数
30
试验地点
2
主要终点
Operative time

研究概览

简要总结

The pilot study will be a First In Human Clinical Trial to evaluate the Endolumik Gastric Calibration Tube and associated methods in a human clinical cohort of 20-30 bariatric patients at two high-volume bariatric programs. During this clinical study, the single-use, disposable Endolumik Gastric Calibration Tube will be used during twenty sleeve gastrectomy operations and gastric bypass operations.

详细描述

Endolumik Inc. has developed a fluorescence-guided calibration device, the Endolumik Gastric Calibration Tube, to improve visualization during bariatric operations. The present pilot study will be a First In Human Clinical Trial to evaluate the Endolumik Gastric Calibration Tube and associated methods in a human clinical cohort of 20-30 bariatric patients at two high-volume bariatric programs. During this clinical study, the single-use, disposable Endolumik Gastric Calibration Tube will be used during twenty sleeve gastrectomy operations and gastric bypass operations. The goal of the present study is to confirm that the Endolumik Gastric Calibration Tube performs similar to predicate devices currently on the market, as well as to get end-user feedback prior to submitting a 510(k) application to the U.S. Food and Drug Administration (FDA).

In this multicenter trial, both study sites are certified as Bariatric Centers of Excellence through the American Society of Metabolic and Bariatric Surgery. The first clinical site is Ruby Memorial Hospital, part of West Virginia University; the second clinical site is Durham Regional Hospital, part of Duke University.

To date, using funding from a West Virginia Clinical & Translational Science Institute Launch Pilot Grant, our team has validated the device and associated methods of fluorescence-guided sleeve gastrectomy and fluorescence-guided gastric bypass in ex-vivo and in-vivo porcine models, as well as human cadaveric tissue models. Based on FDA criteria, this investigational device meets the definition of a Non-Significant Risk (NSR) device; the risk classification document is included with submission materials.

The investigational device provided will have met design controls per FDA code of federal regulation (CFR): 21 CFR 820.30. Endolumik Inc. will serve as the industry sponsor for this study and will donate the devices being used for the protocol to the two participating study sites. Development of the technology in this research is supported by the West Virginia University Department of Surgery.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • English speaking
  • Adults (between age of 18 and 65 years old)
  • Have body mass index (BMI) between 35 and 65.99 kg/m2
  • Male or female bariatric patients undergoing bariatric surgery at one of the two sites included in the protocol.

排除标准

  • Nonbariatric patients
  • Patients who have conditions that preclude a sleeve gastrectomy or gastric bypass operation
  • Patients with esophageal stricture
  • Patients with esophageal varices
  • Patients with a Zenker's diverticulum
  • Patients aged 66 and older
  • Patients with a BMI of 66 kg/m2 or greater
  • Pregnant Women
  • Lactating Women
  • Other vulnerable patient populations: pregnant and lactating women, prisoners, cognitively impaired and critically ill subjects.

结局指标

主要结局

Operative time

时间窗: During surgical treatment

Duration of surgical treatment

Intraoperative adverse events

时间窗: During surgical treatment

Adverse events occurring during surgical treatment

30-day morbidity

时间窗: 30 days post surgical treatment

any 30-day Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) Occurrences

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验